Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

Life Sciences

Volumn 72, Issue 25, 2003, Pages 2915-2921

  Miklya, I ^a   Knoll, J ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

( ) deprenyl (Selegiline); Bromocriptine; Clorgyline; Desmethylimipramine (DMI); Enhancer compounds; Enhancer effect; Fluoxetine; Lazabemide; Pergolide; R ( ) 1 (benzofuran 2 yl) 2 propylaminopentane ( ) BPAP ; phenylethylamine (PEA)

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; BENZOFURAN DERIVATIVE; BROMOCRIPTINE; CLORGYLINE; DESIPRAMINE; DOPAMINE RECEPTOR; FLUOXETINE; LAZABEMIDE; PERGOLIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN STEM; CATECHOLAMINE NERVE CELL; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DOPAMINE RELEASE; ELECTROSTIMULATION; NERVE CONDUCTION; NONHUMAN; NORADRENALIN RELEASE; RAT; RECEPTOR UPREGULATION; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL;

PISUM SATIVUM;

EID: 0037427374     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00197-8     Document Type: Article

References (18)

1. Beasley C.M., Masica D.N., Potvin J.H. Fluoxetine: a review of receptor and functional effect and their clinical implications. Psychopharmacology. 107:1992;1-10.
2. Ekstedt B., Magyar K., Knoll J. Does the B form of selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochemical Pharmacology. 28:1979;919-923.
3. Fuller R.W., Clemens J.A. Pergolide a dopamine agonist at both D1 and D2 receptors. Life Sciences. 49:1991;925-931.
4. Haefely W.E., Kettler R., Keller H.H., Da Prada M. Ro 19-6327 a reversible highly selective monoamine oxidase B inhibitor: a novel tool to explore the MAO B function in humans. Advances in Neurology. 53:1990;501-512.
5. Knoll J. The pharmacology of selegiline /(-)deprenyl/. New aspects. Acta Neurologica Scandinavica. 126:1989;83-91.
6. Knoll J. Memories of my 45 years in research. Pharmacology & Toxicology. 75:1994;65-72.
7. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacology & Toxicology. 82:1998;57-66.
8. Knoll J. Antiaging compounds: (-)Deprenyl (Selegiline) and (-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. CNS Drug Reviews. 7:2001;317-345.
9. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Advances Biochemical Psychopharmacology. 5:1972;393-408.
10. Knoll J., Ecseri Z., Kelemen K., Nievel J., Knoll B. Phenylisopropylmethyl- propinylamine (E-250) a new psychic energizer. Archives internationales de Pharmacodynamie et de Thérapie. 155:1965;154-164.
11. Knoll J., Knoll B., Török Z., Timár J., Yasar S. The pharmacology of 1-phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Archives internationales de Pharmacodynamie et de Thérapie. 316(1/2):1992;5-29.
12. Knoll J., Miklya I., Knoll B., Markó R., Rácz D. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sciences. 58:1996;2101-2114.
13. Knoll J., Yoneda F., Knoll B., Ohde H., Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. British Journal of Pharmacology. 128:1999;1723-1732.
14. Oka T., Yasusa T., Ando T., Watanabe M., Yoneda F., Ishida T., Knoll J. Enantioselective synthesis and absolute configuration of (-)1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP, a highly potent and selective catecholaminergic activity enhancer. Bioorganic & Medicinal Chemistry. 9:2001;1213-1219.
15. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., Knoll J., Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. European Journal of Pharmacology. 421:2001;181-189.
16. Sulser F., Mobley P.L. Biochemical effects of antidepressants in animals. Hoffmeister F., Stille G. Psychotropic Agents: Antipsychotics and Antidepressants. Handbook of Experimental Pharmacology. vol. 55. Pt. I:1980;471-490 Springer Verlag, Berlin.
17. Traub M., Wagner H.R., Hassan M., Jackson-Lewis V., Fahn S. The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum. European Journal of Pharmacology. 118:1985;147-154.
18. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., Knoll J. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorganic & Medicinal Chemistry. 9:2001;1197-1212.